Imetelstat sodium + Bevacizumab + Paclitaxel
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Recurrent or Metastatic Breast Cancer
Conditions
Locally Recurrent or Metastatic Breast Cancer
Trial Timeline
Nov 1, 2010 → Dec 1, 2012
NCT ID
NCT01256762About Imetelstat sodium + Bevacizumab + Paclitaxel
Imetelstat sodium + Bevacizumab + Paclitaxel is a phase 2 stage product being developed by Geron for Locally Recurrent or Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01256762. Target conditions include Locally Recurrent or Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01256762 | Phase 2 | Completed |
Competing Products
20 competing products in Locally Recurrent or Metastatic Breast Cancer